FrancophonIA/ELRC3.0 huggingface dataset:
English: The absolute bioavailability of a single 600 mg dose of darunavir alone was approximately 37% and increased to approximately 82% in the presence of 100 mg twice daily ritonavir.
Slovenian: Absolutna biološka uporabnost enkratnega 600-miligramskega odmerka samega darunavirja je bila približno 37% in se je povečala na približno 82% v prisotnosti 100 mg ritonavirja dvakrat na dan. Absolutna biološka uporabnost emtricitabina v 200-miligramskih kapsulah je bila 93%.
English: Tenofovir alafenamide is permeable into cells and due to increased plasma stability and intracellular activation through hydrolysis by cathepsin A, tenofovir alafenamide is more efficient than tenofovir disoproxil in concentrating tenofovir in peripheral blood mononuclear cells (PBMC) (including lymphocytes and other HIV target cells) and macrophages.
Slovenian: Alafenamidtenofovirat vstopa v celice in zaradi večje stabilnosti v plazmi in znotrajcelične aktivacije, ki jo omogoča hidroliza s katepsinom A, v primerjavi z dizoproksiltenofoviratom bolj učinkovito koncentrira tenofovir v enojedrnih celicah periferne krvi (PBMC-Peripheral Blood Mononuclear Cells) (vključno z limfociti in drugimi tarčnimi celicami, ki jih prizadene virus HIV) in v makrofagih.
English: Patients had a median age of 15 years (range: 12-17), and 56% were female, 12% were Asian, and 88% were Black.
Slovenian: Mediana starost bolnikov je bila 15 let (od 12 do 17 let), 56% jih je bilo ženskega spola, 12% je bilo pripadnikov azijske rase, 88% pa pripadnikov črne rase.
English: Symtuza should not be used in paediatric patients below 3 years of age because of safety concerns (see sections 4.4 and 5.3).
Slovenian: Zdravila Symtuza se ne sme uporabljati pri pediatričnih bolnikih, mlajših od 3 let, zaradi pomislekov glede varnosti (glejte poglavji 4.4 in 5.3).
English: Viruses selected in these conditions and showing decreased susceptibility to darunavir (range: 23-50-fold) harboured 2 to 4 amino acid substitutions in the protease gene.
Slovenian: Selekcionirani virusi niso mogli rasti pri koncentracijah darunavirja nad 400 nM. Virusi, selekcionirani v teh pogojih, ki so imeli zmanjšano občutljivost na darunavir (od 23-krat do 50-krat), so imeli 2 do 4 substitucije aminokislin v genu za proteazo.
English: Patients with severe (Child-Pugh Class C) hepatic impairment.
Slovenian: Uporaba pri bolnikih s hudo okvaro jeter (Child-Pugh razreda C).
English: Although darunavir has not been studied in patients with renal impairment, population pharmacokinetic analysis showed that the pharmacokinetics of darunavir were not significantly affected in HIV infected patients with moderate renal impairment (eGFRCG between 30-60 mL/min, N = 20) (see sections 4.2 and 4.4).
Slovenian: Čeprav darunavirja niso preučevali pri bolnikih z okvaro ledvic, je populacijska analiza farmakokinetike pokazala, da farmakokinetika darunavirja ni pomembno spremenjena pri bolnikih z okužbo z virusom HIV in zmerno okvaro ledvic (eGFRCG od 30 do 60 ml/min, n = 20) (glejte poglavji 4.2 in 4.4).
English: Your doctor should do blood tests before you start Symtuza.
Slovenian: Zdravnik bo opravil krvne preiskave, preden vam bo predpisal zdravilo Symtuza.
English: At Week 48 changes from baseline were smaller with D/C/F/TAF than D/C+F/TDF.
Slovenian: Po koncu 48. tedna so bile spremembe od izhodiščnih vrednosti manjše v skupini D/C/F/TAF kot v skupini D/C+F/TDF.
English: Darunavir and cobicistat are metabolised by CYP3A.
Slovenian: Darunavir in kobicistat se presnavljata s CYP3A.
English: Patients should be informed that dizziness may occur when treated with Symtuza (see section 4.8).
Slovenian: Bolnike je treba opozoriti, da v času zdravljenja z zdravilom Symtuza lahko pride do omotičnosti (glejte poglavje 4.8).
English: Virologic Outcomes in AMBER at Week 48 and 96 (FDA Snapshot) Week 48
Slovenian: Virološki izidi v študiji AMBER po 48 in 96 tednih (posnetek stanja, ki ga je opravila Ameriška agencija za hrano in zdravila, FDA Snapshot) po 48 tednih po 96 tednih*
English: When administration of HMG CoA reductase inhibitors and Symtuza is desired, it is recommended to start with the lowest dose and titrate up to the desired clinical effect while monitoring for safety.
Slovenian: Če bi želeli, da bolnik uporablja katerega od zaviralcev reduktaze HMG COA in zdravilo Symtuza, je priporočljivo, da zdravljenje začnete z najmanjšim odmerkom, ki ga nato, ob spremljanju varnosti, povečujete do kliničnega učinka.
English: Based on theoretical considerations, no mechanistic interaction is expected.
Slovenian: Glede na teoretična izhodišča mehanističnih interakcij ni pričakovati.
English: C]-cobicistat, 99% of circulating radioactivity in plasma was unchanged cobicistat.
Slovenian: C označenega kobicistata je 99% radioaktivnosti v krvnem obtoku predstavljal nespremenjeni kobicistat.
English: The exposure to cobicistat was lower during pregnancy, potentially leading to suboptimal boosting of darunavir.
Slovenian: Med nosečnostjo je bila izpostavljenost kobicistatu manjša, kar je lahko zmanjšalo okrepitev darunavirja.
English: Limited information is available in this population, and, therefore, Symtuza should be used with caution in patients above 65 years of age (see sections 4.4 and 5.2).
Slovenian: Podatki pri tej populaciji bolnikov so omejeni, zato je pri uporabi zdravila Symtuza pri bolnikih, starih več kot 65 let, potrebna previdnost (glejte poglavji 4.4 in 5.2).
English: In HIV infected patients with severe immune deficiency at the time of initiation of CART, an inflammatory reaction to asymptomatic or residual opportunistic pathogens may arise and cause serious clinical conditions, or aggravation of symptoms.
Slovenian: Pri bolnikih, okuženih s HIV, s hudo imunsko pomankljivostjo ob uvedbi CART, se lahko pojavi vnetna reakcija na asimptomatske ali prikrite oportunistične okužbe in povzroči resna klinična stanja ali poslabšanje simptomov.
English: Concomitant use of a HMG CoA reductase inhibitor and Symtuza may increase plasma concentrations of the lipid lowering agent, which may lead to adverse reactions such as myopathy.
Slovenian: Sočasna uporaba katerega od zaviralcev reduktaze HMG COA in zdravila Symtuza lahko poveča plazemske koncentracije zdravila za zniževanje koncentracije lipidov, kar lahko povzroča neželene učinke, kot je miopatija.
English: Treatment with darunavir/cobicistat (two of the components of Symtuza) during pregnancy results in low darunavir exposure (see sections 4.4 and 5.2).
Slovenian: Zdravljenje s kombinacijo darunavir/kobicistat (z dvema od učinkovin v zdravilu Symtuza) med nosečnostjo zmanjša izpostavljenost darunavirju (glejte poglavji 4.4 in 5.2).
English: In a multiple dose trial with darunavir/ritonavir (600/100 mg) twice daily, it was demonstrated that the total plasma concentrations of darunavir in subjects with mild (Child-Pugh Class A, N = 8) and moderate (Child-Pugh Class B, N = 8) hepatic impairment were comparable with those in healthy subjects.
Slovenian: V preskušanju večkratnih odmerkov darunavirja/ritonavirja (600/100 mg dvakrat na dan) se je pokazalo, da so bile celokupne plazemske koncentracije darunavirja pri posameznikih z blago (razred A po Child-Pughovi lestvici, n = 8) in srednje hudo okvaro jeter (razred B po Child-Pughovi lestvici, n = 8) primerljive s tistimi pri zdravih osebah.
English: The use of Symtuza in ART-naïve adolescent patients from the age of 12 years to < 18 years, and weighing at least 40 kg is supported by two trials in HIV-1 infected paediatric patients (TMC114-C230 and GS-US-292-0106).
Slovenian: Uporabo zdravila Symtuza pri mladostnikih, starih 12 do < 18 let in s telesno maso najmanj 40 kg, ki predhodno še niso prejemali protiretrovirusnega zdravljenja, podpirajo rezultati dveh preskušanj pri pediatričnih bolnikih, okuženih v virusom HIV-1 (TMC114-C230 in GS-US-292-0106).
English: Treatment with darunavir/cobicistat 800/150 mg once daily during pregnancy results in low darunavir exposure (see Table 8).
Slovenian: Zdravljenje s kombinacijo darunavir/kobicistat 800/150 mg enkrat na dan med nosečnostjo povzroča zmanjšanje izpostavljenosti darunavirju (glejte Preglednico 8).
English: When your supply of Symtuza starts to run low, get more from your doctor or pharmacist.
Slovenian: Ko se vaše zaloge zdravila Symtuza zmanjšajo, si zdravilo priskrbite pri zdravniku ali farmacevtu.
English: The effect of severe hepatic impairment (Child-Pugh Class C) on the pharmacokinetics of tenofovir alafenamide has not been studied.
Slovenian: Vpliva hude okvare jeter (razreda C po Child-Pughovi lestvici) na farmakokinetiko alafenamidtenofovirata niso preučevali.
English: Patients were virologically suppressed for at least 2 months and no more than once had a viral load elevation above 50 HIV-1 RNA copies/mL during the year prior to enrollment.
Slovenian: Pri bolnikih je virološka supresija trajala najmanj 2 meseca, pri tem pa je v letu pred vključitvijo v študijo največ enkrat prišlo do povečanja virusnega bremena nad 50 HIV-1 RNK kopij/ml.
English: 2.7 (95% CI: -1.6; 7.1)
Slovenian: 2,7 (95% IZ: -1,6; 7,1)
English: Autoimmune disorders (such as Graves' disease and autoimmune hepatitis) have also been reported; however, the reported time to onset is more variable, and these events can occur many months after initiation of treatment (see section 4.4).
Slovenian: Poročali so tudi o avtoimunskih bolezni (kot je Gravesova bolezen in avtoimunski hepatitis), vendar je čas do njihovega nastanka različen in se lahko pojavijo tudi več mesecev po začetku zdravljenja (glejte poglavje 4.4).
English: Median Increase From Baseline at Week 48 D/C/F/TAF
Slovenian: Mediano povečanje vrednosti od izhodiščne v 48. tednu D/C/F/TAF
English: Medicinal products that induce P-gp activity (e.g., rifampicin, rifabutin, carbamazepine, phenobarbital) are expected to decrease the absorption of tenofovir alafenamide, resulting in decreased plasma concentration of tenofovir alafenamide, which may lead to loss of therapeutic effect of tenofovir alafenamide and development of resistance.
Slovenian: Za zdravila, ki inducirajo aktivnost Pglikoproteina, (npr. rifampicin, rifabutin, karbamazepin, fenobarbital) se pričakuje, da zmanjšajo absorpcijo alafenamidtenofovirata, kar povzroči znižanje koncentracije alafenamidtenofovirata v plazmi, to pa lahko zmanjša njegov terapevtski učinek in povzroči razvoj rezistence.
English: • Remove the unscrewed cap.
Slovenian: • Snemite odvito zaporko.
English: The intravenous clearance of darunavir alone (150 mg) and in the presence of low dose (100 mg) ritonavir was 32.8 l/h and 5.9 l/h, respectively.
Slovenian: Intravenski očistek samega darunavirja (150 mg) je bil 32,8 l/h, v prisotnosti majhnega odmerka ritonavirja (100 mg) pa 5,9 l/h.
English: Do not take Symtuza - if you are allergic (hypersensitive) to darunavir, cobicistat, emtricitabine, tenofovir alafenamide, or any of the other ingredients of Symtuza (listed in section 6).
Slovenian: Ne jemljite zdravila Symtuza - če ste alergični (preobčutljivi) na darunavir, kobicistat, emtricitabin, alafenamidtenofovirat ali ali katero koli sestavino tega zdravila (navedeno v poglavju 6); - če imate hude težave z jetri.
English: The dosage of other medicines might need to be changed since either their own or Symtuza's therapeutic effect or side effects may be influenced when combined.
Slovenian: Lahko bo potrebna tudi sprememba odmerjanja drugih zdravil, zaradi vpliva kombinacije na terapevtske ali neželene učinke teh zdravil ali zdravila Symtuza.
English: In HIV infected patients with severe immune deficiency at the time of CART, an inflammatory reaction to asymptomatic or residual opportunistic infections may arise.
Slovenian: Pri bolnikih okuženih z virusom HIV, ki imajo ob uvedbi CART hudo imunsko pomanjkljivost, se lahko pojavi vnetna reakcija na asimptomatične ali rezidualne oportunistične okužbe.
English: For tenofovir alafenamide, the Cmax was 1.82-fold higher in fasted condition, while the AUC was 20% lower to comparable in a fasted compared to fed condition.
Slovenian: Cmax alafenamidtenofovirata je bila 1,82-krat večja po odmerjanju zdravila na tešče, AUC pa je bila 20% manjša do približno enaka po zaužitju zdravila na tešče v primerjavi z zaužitjem zdravila po hrani.
English: INHALED BETA AGONISTS Salmeterol
Slovenian: INHALACIJSKI AGONISTI ADRENERGIČNIH RECEPTORJEV BETA salmeterol
English: The overall safety profile of Symtuza is based on data from a randomised, double-blinded, comparative Phase 2 trial, GS-US-299-0102 (N = 103 on darunavir/cobicistat/emtricitabine/tenofovir alafenamide [D/C/F/TAF]), data from 2 Phase 3 trials TMC114FD2HTX3001 (AMBER, N = 362 on D/C/F/TAF) and TMC114IFD3013 (EMERALD, N = 763 on D/C/F/TAF), and on all available clinical trial and post-marketing data of its components.
Slovenian: Celokupen varnostni profil zdravila Symtuza temelji na podatkih randomiziranega, dvojno slepega, primerjalnega preskušanja faze 2 z oznako GS-US-299-0102 (n = 103 bolniki s kombinacijo darunavir/kobicistat/emtricitabin/alafenamidtenofovirat [D/C/F/TAF]), podatkih dveh preskušanj faze 3 z oznako TMC114FD2HTX3001 (AMBER, N = 362 bolnikov s kombinacijo D/C/F/TAF) in TMC114IFD3013 (EMERALD, N = 763 bolnikov s kombinacijo D/C/F/TAF) in vseh razpoložljivih podatkih o posameznih učinkovinah zdravila iz kliničnih preskušanj in izkušenj v obdobju trženja zdravila.
English: In the Phase 2/3 trials in treatment-naïve patients, 12.7% (59/465) of patients receiving Symtuza experienced rash (most of which were grade 1), 1.5% (7/465) of patients discontinued treatment due to rash, of whom one for rash and hypersensitivity.
Slovenian: V preskušanjih faze 2/3 pri predhodno nezdravljenih bolnikih se je pri 12,7% (59/465) bolnikov, ki so prejemali zdravilo Symtuza, pojavil izpuščaj (v večini primerov stopnje 1), 1,5% (7/465) bolnikov pa je prekinilo zdravljenje zaradi izpuščaja, med njimi en bolnik zaradi izpuščaja in preobčutljivosti.
English: There is no specific antidote for overdose with Symtuza.
Slovenian: Za preveliko odmerjanje zdravila Symtuza ni specifičnega antidota.
English: Patients had a median age of 46 years (range 19-78), 82% were male, 75.5% White, 20.9% Black, and 2.3% Asian.
Slovenian: Mediana starost bolnikov je bila 46 let (stari so bili od 19 do 78 let), 82% je bilo moških, 75,5% je bilo belcev, 20,9% pripadnikov črne rase in 2,3% pripadnikov azijske rase.
English: Pack size of one bottle or three bottles per carton.
Slovenian: Pakiranje z eno ali tremi plastenkami v škatli.
English: Emerging resistance in the Symtuza groups is shown in Table 4.
Slovenian: V preglednici 4 je prikazano pojavljanje odpornosti v skupinah z zdravilom Symtuza.
English: In case of concomitant antiviral therapy for hepatitis C, please refer also to the relevant Summary of Product Characteristics for these medicinal products.
Slovenian: V primeru sočasnega protiretrovirusnega zdravljenja z več zdravili za hepatitis C, glejte tudi povzetke glavnih značilnosti posameznega zdravila
English: Darunavir binds primarily to plasma α1-acid glycoprotein.
Slovenian: Veže se predvsem na plazemski α1-kisli glikoprotein.
English: Due to an increase in the unbound darunavir plasma concentrations, Symtuza should be used with caution in patients with mild or moderate hepatic impairment (see sections 4.2, 4.3 and 5.2).
Slovenian: Zaradi povečanja plazemskih koncentracij nevezanega darunavirja, je treba pri bolnikih z blago ali zmerno okvaro jeter zdravilo Symtuza uporabljati previdno (glejte poglavja 4.2, 4.3 in 5.2).
English: Do not stop taking Symtuza without talking to your doctor first
Slovenian: Ne prenehajte jemati zdravila Symtuza, ne da bi se prej posvetovali s svojim zdravnikom.
English: Thirteen percent of the emtricitabine dose was recovered in urine as three metabolites.
Slovenian: Trinajst odstotkov odmerka emtricitabina so izolirali v urinu v obliki treh presnovkov.
English: Symtuza and antacids can be used concomitantly without dose adjustment.
Slovenian: Zdravilo Symtuza in antacide se sočasno lahko uporablja brez prilagajanja odmerkov.
English: Emtricitabine triphosphate inhibits HIV replication through incorporation into viral DNA by the HIV reverse transcriptase (RT), which results in DNA chain-termination.
Slovenian: Emtricitabin trifosfat zavira replikacijo virusa HIV tako, da se vgradi v virusno DNK s pomočjo reverzne transkriptaze virusa HIV, kar povzroči prekinitev podaljševanja verige DNK.
English: Its use should only take place after medical evaluation and under close monitoring by your doctor for corticosteroid side effects.
Slovenian: Ta zdravila se lahko uporabljajo le po zdravniškem pregledu in ob natančnem zdravniškem spremljanju zaradi možnosti pojava neželenih učinkov, povezanih s kortikosteroidi.
English: Symtuza must not be used with another antiviral medicine that contains a booster or another antiviral that requires boosting.
Slovenian: Zdravila Symtuza se ne sme uporabljati skupaj z drugim protivirusnim zdravilom, ki vsebuje ojačevalec, ali z drugim protivirusnim zdravilom, ki potrebuje okrepitev z ojačevalcem.
English: Intracellular tenofovir is subsequently phosphorylated to the pharmacologically active metabolite tenofovir diphosphate.
Slovenian: Znotrajcelični tenofovir se nato fosforilizira v farmakološko aktivni presnovek tenofovir difosfat.
English: - lopinavir/ritonavir - St. John's wort (Hypericum perforatum)
Slovenian: - rifampicin - lopinavir/ritonavir - šentjanževka (Hypericum perforatum)
English: Protocol Defined Rebound Rate (95% CI)
Slovenian: stopnja s protokolom opredeljenega povratnega odziva (95-odstotni IZ) razlika med deležema
English: In vivo, tenofovir alafenamide is hydrolysed within cells to form tenofovir (major metabolite), which is phosphorylated to the active metabolite tenofovir diphosphate.
Slovenian: In vivo se alafenamidtenofovirat hidrolizira v celici, da nastane tenofovir (glavni presnovek), ta pa se fosforilizira v aktivni presnovek tenofovir difosfat.
English: With ritonavir-boosted darunavir, a small decrease in methadone plasma concentrations was observed.
Slovenian: Pri uporabi darunavirja, okrepljenega z ritonavirjem so opazili blago zmanjšanje plazemske koncentracije metadona.
English: Via C. Janssen, Borgo San Michele
Slovenian: Janssen-Cilag SpA Via C. Janssen, Borgo San Michele
English: HIV-1 RNA ≥ 50 copies/mL Virologic Failure Leading to Discontinuation Discontinued study drug due to other reasons and last available HIV-1 RNA ≥ 50 copies/mL
Slovenian: HIV-1 RNK ≥ 50 kopij/ml prekinitev zdravljenja zaradi virološkega neuspeha prekinitev zdravljenja zaradi drugih vzrokov in zadnja razpoložljiva vrednost HIV-1 RNK ≥ 50 kopij/ml
English: At baseline, median plasma HIV-1 RNA was 4.7 log10 copies/mL, median CD4+ cell count was 456 cells/mm
Slovenian: Ob izhodišču je bila mediana vrednost HIV-1 RNK v plazmi 4,7 log10 kopij/ml, mediano število celic CD4+ je bilo 456 celic/mm
English: Cobicistat is metabolised via CYP3A (major)- and CYP2D6 (minor)-mediated oxidation and does not undergo glucuronidation.
Slovenian: Kobicistat se presnavlja z oksidacijo s pomočjo CYP3A (glavna pot) in s CYP2D6 (manj pomembna pot), ni pa podvržen glukuronidaciji.
English: • abnormal blood test results such as some tests for your pancreas.
Slovenian: • nenormalni izvidi krvnih preiskav, kot so testi delovanja ledvic.
English: No teratogenic effects were observed in rats and rabbit developmental toxicity studies.
Slovenian: V študijah razvojne toksičnosti na podganah in kuncih niso opažali teratogenega delovanja.
English: The 725 patients in total had a median age of 34 years (range 18-71), 88.3% were male, 83.2% White, 11.1% Black, 1.5% Asian.
Slovenian: Skupno je bilo vključenih 725 bolnikov z mediano starostjo 34 let (od 18 do 71 let), 88,3% je bilo moških, 83,2% je bilo belcev, 11,1% pripadnikov črne rase in 1,5% pripadnikov azijske rase.
English: The pharmacokinetics of Symtuza have not been investigated in paediatric patients.
Slovenian: Farmakokinetike zdravila Symtuza pri pediatričnih bolnikih niso preučevali.
English: In vitro binding of emtricitabine to human plasma proteins was < 4% and independent of concentration over the range of 0.02-200 mcg/mL.
Slovenian: In vitro vezava emtricitabina na humane plazemske beljakovine je bila manjša od 4% in neodvisna od koncentracije v razponu od 0,02 in 200 µg/ml.
English: Amitriptyline Desipramine Imipramine Nortriptyline Trazodone
Slovenian: paroksetin sertralin amitriptilin dezipramin imipramin nortriptilin trazodon
English: Symtuza might increase sugar levels in the blood.
Slovenian: Zdravilo Symtuza lahko poveča koncentracijo sladkorja v krvi.
English: Patients co-infected with hepatitis B and/or hepatitis C virus Limited information is available on the use of Symtuza components in patients co-infected with hepatitis B and/or C virus.
Slovenian: Bolniki, sočasno okuženi z virusom hepatitisa B in/ali virusom hepatitisa C O uporabi učinkovin zdravila Symtuza pri bolnikih s sočasno okužbo z virusom hepatitisa B in/ali virusom hepatitisa C je na voljo le malo podatkov.
English: Nervous system disorders very common headache common dizziness
Slovenian: Bolezni živčevja zelo pogosti glavobol občasni omotičnost
English: As Symtuza contains darunavir, cobicistat, emtricitabine, and tenofovir alafenamide, the adverse reactions associated with each of the individual compounds may be expected.
Slovenian: Zdravilo Symtuza vsebuje darunavir, kobicistat, emtricitabin in alafenamidtenofovirat, zato je mogoče pričakovati neželene učinke, ki so povezani z vsako od posameznih učinkovin.
English: Tenofovir diphosphate inhibits HIV replication through incorporation into viral DNA by the HIV RT, which results in DNA chain-termination.
Slovenian: Tenofovir difosfat zavira replikacijo virusa HIV tako, da se vgradi v virusno DNK s pomočjo reverzne transkriptaze virusa HIV, kar povzroči prekinitev podaljševanja verige DNK.
English: Clinically relevant changes in tenofovir pharmacokinetics in patients with hepatic impairment were not observed in patients with mild to moderate hepatic impairment.
Slovenian: Klinično pomembnih sprememb v farmakokinetičnih lastnostih tenofovirja pri bolnikih z blago do zmerno okvaro jeter niso opažali.
English: The most frequent (> 5%) adverse reactions reported in treatment-naïve patients in the Phase 2 (GSUS-299-0102) and Phase 3 Study (AMBER, TMC114FD2HTX3001, Week 96 analysis) were diarrhoea (22.6%), headache (13.1%), rash (12.7%), nausea (9.7%), fatigue (8.0%), and abdominal pain (5.8%).
Slovenian: Najpogostejši neželeni učinki (>5%), o katerih so poročali pri predhodno nezdravljenih bolnikih v preskušanju faze 2 (GS-299-0102) in preskušanju faze 3 (AMBER, TMC114FD2HTX3001, analiza podatkov po 96 tednih), so bili driska (22,6%), glavobol (13,1%), izpuščaj (12,7%), navzea (9,7%), utrujenost (8,0%) in bolečine v trebuhu (5,8%).
English: Rifampicin to treat some infections such as tuberculosis Pimozide, lurasidone, quetiapine or sertindole to treat psychiatric conditions Ergot alkaloids like ergotamine, dihydroergotamine, ergometrine and methylergonovine to treat migraine headaches
Slovenian: rifampicin zdravljenje nekaterih okužb, kot je tuberkuloza pimozid, lurasidon, kvetiapin ali sertindol zdravljenje psihiatričnih motenj alkaloidi ergot, kot so ergotamin, dihidroergotamin, ergometrin in metilergonovin zdravljenje migrenskih glavobolov šentjanževka (Hypericum perforatum)
English: Relevant examples include cytomegalovirus retinitis, generalised and/or focal mycobacterial infections and pneumonia caused by Pneumocystis jirovecii
Slovenian: Sem sodijo citomegalovirusni retinitis, generalizirane in/ali fokalne mikobakterijske okužbe in pljučnica, ki jo povzroča Pneumocystis jirovecii (prej znana kot Pneumocystis carinii).
English: Darunavir exhibits activity against laboratory strains and clinical isolates of HIV-1 and laboratory strains of HIV-2 in acutely infected T-cell lines, human PBMCs and human monocytes/macrophages with median EC50 values ranging from 1.2 to 8.5 nM (0.7 to 5.0 ng/mL).
Slovenian: Darunavir je pokazal učinkovitost proti laboratorijskim sevom in kliničnim izolatom HIV-1 in proti laboratorijskim sevom HIV-2 v akutno okuženih celičnih linijah T celic, človeških mononuklearnih celicah periferne iz krvi in človeških monocitih/makrofagih z medianimi vrednostmi EC50 v razponu od 1,2 do 8,5 nM (0,7 do 5,0 ng/ml).